Mark Iwicki, Kala Pharmaceuticals CEO (Merus)
Alcon takes a crack at multibillion-dollar dry eye market, picks up 2 drugs from Langer spinout
Kala Pharmaceuticals may have never come close to the blockbuster dreams it had for its dry eye disease treatment, but Alcon wants to see if …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
